Benefits of biomarkers in heart failure

Article
  • 7 Downloads

References

  1. 1.
    Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148–2159PubMedCrossRefGoogle Scholar
  2. 2.
    La Vecchia L, Mezzena G, Zanolla L, Paccanaro M, Varotto L, Bonanno C, Ometto R (2000) Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 19:644–652PubMedCrossRefGoogle Scholar
  3. 3.
    Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y (2001) Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 103:369–374PubMedGoogle Scholar
  4. 4.
    Missov E, Calzolari C, Pau B (1997) Circulating cardiac troponin I in severe congestive heart failure. Circulation 96:2953–2958PubMedGoogle Scholar
  5. 5.
    Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, Takano T, Kishida H, Hayakawa H (1999) Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 84:608–611PubMedCrossRefGoogle Scholar
  6. 6.
    Del Carlo CH, O'Connor CM (1999) Cardiac troponins in congestive heart failure. Am Heart J 138:646–653PubMedCrossRefGoogle Scholar
  7. 7.
    Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E (1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335:1342–1349PubMedCrossRefGoogle Scholar
  8. 8.
    Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 335:1333–1341PubMedCrossRefGoogle Scholar
  9. 9.
    Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, Davis B, Habib G, Roberts R (1999) Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 99:1671–1677PubMedGoogle Scholar
  10. 10.
    Horwich TB, Patel J, MacLellan WR, Fonarow GC (2003) Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108:833–838PubMedCrossRefGoogle Scholar
  11. 11.
    Rehman S, Lloyd-Jones DM, Martinez-Rumayor A, Januzzi JL (2008) Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients. Am J Clin Pathol 130:305–311PubMedCrossRefGoogle Scholar
  12. 12.
    De Lemos JA, Lloyd-Jones DM (2008) Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med 358:2172–2174PubMedCrossRefGoogle Scholar
  13. 13.
    Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, Gaulden LH, Sedor F, Ohman EM (2004) Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 147:546–552PubMedCrossRefGoogle Scholar
  14. 14.
    Perna ER, Macín SM, Cimbaro Canella JP, Alvarenga PM, Ríos NG, Pantich R, Augier N, Farías EF, Jantus E, Brizuela M, Medina F (2005) Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int J Cardiol 99:253–261PubMedCrossRefGoogle Scholar
  15. 15.
    Peacock WF IV, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH, ADHERE Investigators (2008) Cardiac troponin and outcome in acute heart failure. N Engl J Med 358:2117–2126PubMedCrossRefGoogle Scholar
  16. 16.
    Fonarow GC, Peacock WF, Horwich TB, Phillips CO, Givertz MM, Lopatin M, Wynne J, ADHERE Scientific Advisory Committee and Investigators (2008) Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 101:231–237PubMedCrossRefGoogle Scholar
  17. 17.
    Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242–1249PubMedCrossRefGoogle Scholar
  18. 18.
    Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357–2368PubMedCrossRefGoogle Scholar
  19. 19.
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167PubMedCrossRefGoogle Scholar
  20. 20.
    Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954PubMedCrossRefGoogle Scholar
  21. 21.
    Mueller C, Laule-Kilian K, Scholer A, Frana B, Rodriguez D, Schindler C, Marsch S, Perruchoud AP (2004) Use of B-type natriuretic peptide for the management of women with dyspnea. Am J Cardiol 94:1510–1514PubMedCrossRefGoogle Scholar
  22. 22.
    Januzzi JL Jr, Chen-Tournoux AA, Moe G (2008) Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 101:29–38PubMedCrossRefGoogle Scholar
  23. 23.
    Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, ADHERE Scientific Advisory Committee, Study Group, and Investigators (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293:572–580PubMedCrossRefGoogle Scholar
  24. 24.
    Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, Dohi Y (2005) Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail 11:504–509PubMedCrossRefGoogle Scholar
  25. 25.
    Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ (2005) B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46:610–620PubMedCrossRefGoogle Scholar
  26. 26.
    Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 49:1733–1739PubMedCrossRefGoogle Scholar
  27. 27.
    Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC (2004) Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43:635–641PubMedCrossRefGoogle Scholar
  28. 28.
    Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, Hall C, Latini R, Afzal R, Floras J, Masson S, McKelvie RS, Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators (2005) Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 96:698–704PubMedCrossRefGoogle Scholar
  29. 29.
    Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS (2007) Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 116:249–257PubMedCrossRefGoogle Scholar
  30. 30.
    Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283PubMedCrossRefGoogle Scholar
  31. 31.
    Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN, Val-HeFT Investigators (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003PubMedCrossRefGoogle Scholar
  32. 32.
    Gardner RS, Chong KS, Morton JJ, McDonagh TA (2007) A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur J Heart Fail 9:266–271PubMedCrossRefGoogle Scholar
  33. 33.
    Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Allgemeine und Interventionelle KardiologieUniversitäres Herzzentrum HamburgHamburgGermany

Personalised recommendations